TB Clip July 2023 article image

편집자 한마디!

국내외 결핵(TB)뉴스

학술연구자료

STOP-TB한국사무국 소식

The Lancet Global Health에 발표된 새로운 연구에 따르면 HIV에 걸린 사람들과 새로 결핵 진단을 받은 개인 접촉자들에게 short-course options을 포함한 결핵예방치료(TPT)는 활동성 결핵으로의 진행을 예방하는 데 효과적이기에 2035년까지 850,000명의 생명을 구할 수 있다고 합니다. 또한 단기 TPT는 대부분의 국가에서 5세 미만의 아동 접촉자 뿐만 아니라 5세 이상의 아동 및 성인 접촉자에 대해서도 cost-effective할 가능성이 높다고 하니, 국내에서도 단기 TPT의 도입이 시급해 보입니다.

The World Health Organization (WHO) released two information notes with practical guidance for clinicians and care givers, as well as community health workers, on the dosing and administration of bedaquiline and delamanid in children and adolescents with drug-resistant TB. The information notes complement the updated WHO guidelines and operational handbook on the management of TB in children and adolescents released in 2022.

The World Health Organization (WHO) Global TB Program has created an online platform to help users find practical advice to implement digital technologies to support TB care worldwide. The platform includes easy access to guidelines and job aids developed by WHO and technical partners, as well as links to key literature and country examples.

The World Health Organization (WHO) launched two new e-courses on national strategic planning for TB and systematic screening for TB disease. The new WHO e-courses have been added to the End TB Channel in OpenWHO. They are free of charge and self-paced. A certificate can be downloaded if a 80% score or higher is achieved in the final assessment. For detailed information about the e-courses, click here .

The World Health Organization Regional Office for Europe (WHO/Europe) released a standardized package of community-based support services aiming to improve TB outcomes and assist countries in eastern Europe and central Asia in implementing a new care model to detect and treat drug-resistant TB at an early stage.

The G20 includes many countries with a high burden of TB and is uniquely positioned to lead TB vaccine development and delivery through joint, sustained, and scaled-up investments. A policy brief outlines recommendations for G20 members to act together to accelerate TB vaccine development. At least one new TB vaccine must be licensed and approved by 2025 to meet the World Health Organization’s goal of ending TB by 2030.

The TB Vaccine Advocacy Roadmap (TB Vax ARM) developed a one-pager on why Member States must commit to invest in TB vaccine research and development (R&D). It provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research to reach the annual $1.25 billion funding target and develop and roll-out new TB vaccines within the next five years, no later than 2028.

Before SARS-CoV-2, the virus that causes COVID-19, spread across the world in 2020, TB was responsible for more deaths globally than any other infectious disease. During the pandemic, it at first appeared that, as with many other common illnesses like the flu, COVID-19 prevention efforts reduced TB cases, too. But TB numbers have quickly climbed back up to pre-pandemic levels, marking the first time in decades that cases and deaths have risen globally. Source: The Conversation

No other disease in South Africa kills as many people as TB. To change this, the health department has a new plan for curbing TB infections. With the new guidelines, everyone who has had 'significant exposure' to TB can now get TB preventive medicines, regardless of HIV status or age, and there are four different treatment options. Source: Bhekisisa

Indonesia is ranked as the second-largest TB burden country in the world after India with an estimated number of cases reaching 969,000. Since the end of 2022, the Indonesian government has accelerated detection levels, from previous counts of 540,000 to now 720,000 people with TB. In a special meeting on TB elimination held by President Joko Widodo on 18 July 2023, a new package of interventions was announced to strengthen the national TB response. Source: Stop TB Partnership

Wellcome and the Bill & Melinda Gates Foundation announced USD 550 million funding to advance a TB vaccine candidate, M72/AS01E, through a Phase III clinical trial. If proven effective, M72/AS01E could potentially become the first new vaccine to help prevent pulmonary TB in more than 100 years.

The UK Health Security Agency released a report presenting people with TB disease notified to the enhanced surveillance scheme in England and aiming to describe the epidemiology of TB in England up to the end of 2021. It is the sixth in a series of 7 reports that will describe different aspects of TB incidence, treatment and prevention in England. The report can be accessed here.

Rapid diagnosis and treatment are crucial in the fight against TB. But today's testing methods are not good enough. Tests based on blood biomarkers may be the solution. Source: University of Oslo.

A panel of 65 global experts have identified eight clinical standards for the management of adverse effects during treatment for TB, aiming to encourage best practice for the diagnosis and management of adverse effects.

A new study, published in The Lancet Global Health, found that the lives of 850,000 people could be saved by 2035 if short-course TB preventive treatment is provided to people living with HIV and contacts of individuals newly diagnosed with TB. 700,000 of those lives saved would be among children aged 15 years and younger.

According to a new study, published in BMJ Global Health, introducing novel TB vaccines in low- and middle-income countries has potential to reduce income-based inequalities in health and economic effects.

Bacille Calmette-Guérin (BCG) vaccine is the only available TB vaccine but is of limited effectiveness. Scientists have provided fresh insights into the behaviour of a crucial cell in vaccine mechanisms, which may offer a fresh target for scientists seeking to improve BCG vaccine efficacy.

The first clinical trial of a three-month TB treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment. The CLO-FAST trial sought to evaluate the safety and efficacy of a three-month clofazimine- and high-dose rifapentine-containing regimen in drug-susceptible TB.

lobal efforts to reduce infectious disease rates must have a greater focus on older children and adolescents after a shift in disease burden onto this demographic. According to a new study, the policy focus must be widened to include older children and adolescents and more action taken to prevent TB and HIV.

Rising CD4 counts and suppressed viral load on antiretroviral treatment have had a far greater impact on reducing new TB cases in people with HIV in Switzerland than testing and preventive treatment for latent TB.

All-cause mortality risk was found to be increased among patients with co-occurring diabetes and HIV infection receiving treatment for TB infection, according to a study published in Open Forum Infectious Diseases.

In a study published in EMBO Journal, researchers examined how two new compounds attack the bacteria that cause TB, providing insights that may inform future drug therapies.

Researchers developed nanoparticles to deliver new antibiotics directly to the lungs in future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and can be inhaled. First tests revealed a high effectiveness and good compatibility of the nanocarriers of antibiotics.

In a study, published in the Journal of Infection, researchers performed a systematic literature review of global treatment outcomes of extensively drug-resistant TB. The study found that only 44.2% of affected individuals achieved successful treatment outcomes, which is discouragingly low when accounting for the World Health Organization's goal of achieving 75% treatment success.

According to the World Health Organization, each year there are approximately three million undiagnosed TB cases globally, which are characterized as the 'missing millions'. In a study , published in The Journal of Molecular Diagnostics, scientists tested a diagnostic device using dielectrophoresis that holds promise for improving TB detection and treatment of patients in high-endemic, under-resourced areas.

Increasing prevalence of drug-resistant TB (DR-TB) poses a major challenge to the early detection and effective TB control. A study , published in Tuberculosis, determined the proteomics of exosome in DR-TB and explored the potential pathogenesis of DR-TB.

RESIST-TB released its July 2023 newsletter with the latest updates and research publications on drug-resistant TB.

The International Union Against Tuberculosis and Lung Disease released the July 2023 issue of the International Journal of Tuberculosis and Lung Disease (IJTLD). It includes TB-related research publications.

The International Union Against Tuberculosis and Lung Disease released the June 2023 issue of Public Health Action, a peer-reviewed open access journal. It includes TB-related research publications.